SIHUAN PHARM (00460) announced that the Group made an investment in Swiss medical aesthetics company Suisselle SA (Suisselle) in September 2025, with both parties formally signing an investment subscription agreement. This collaboration will enhance the Group's strategic relationship with Suisselle and jointly expand the global medical aesthetics market.

The Group had already obtained exclusive agency rights for CELLBOOSTER® mesotherapy products in China as early as 2022. This investment will further strengthen the long-term cooperative relationship between both parties. Through this investment, the Group will permanently enjoy exclusive agency rights for CELLBOOSTER® mesotherapy products and deeply participate in its operations and development.

Following SIHUAN PHARM's investment in Suisselle, both parties will collaborate through Suisselle's mature platform in Europe to accelerate the promotion and sales of the Group's self-developed medical aesthetics products under the "Meyan Space" brand in European and other overseas markets. Meanwhile, the Group will continue to introduce Suisselle and other European innovative products to enrich its domestic medical aesthetics product portfolio.

This strategic layout is highly aligned with the Group's globalization strategy, aiming to build an international medical aesthetics ecosystem covering research and development, production, and sales. In recent years, the Group has actively promoted the globalization strategy of its medical aesthetics business. In 2021, it fully acquired American medical aesthetics device company Genesis Biosystems, successfully entering the North American market.

This investment in Suisselle represents a key step in the Group's medical aesthetics industry globalization strategy, marking the formal completion of the Group's strategic layout in the two core medical aesthetics markets of Europe and America. Looking ahead, the Group will continue to rely on the dual-engine approach of independent research and development and international cooperation to promote high-quality medical aesthetics solutions to broader markets, creating long-term sustainable value for shareholders and investors.